The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Marengo Therapeutics
Leadership - Marengo Therapeutics
Stock and Other Ownership Interests - Marengo Therapeutics
Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment.
 
Ryan J. Sullivan
Consulting or Advisory Role - alkermes; Asana Biosciences; AstraZeneca; Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)
 
Ke Liu
Employment - Marengo Therapeutics
Leadership - Marengo Therapeutics
Stock and Other Ownership Interests - Marengo Therapeutics
 
Jason M. Redman
No Relationships to Disclose
 
Nicholas Tschernia
No Relationships to Disclose
 
Andrew Bayliffe
Employment - Marengo Therapeutics
Leadership - Marengo Therapeutics
Stock and Other Ownership Interests - Marengo Therapeutics
 
Alyssa Marino
No Relationships to Disclose
 
Karunya Srinivasan
Employment - Marengo Therapeutics
Stock and Other Ownership Interests - Marengo Therapeutics
 
Madan Katragadda
Employment - Marengo Therapeutics
Leadership - Marengo Therapeutics
Stock and Other Ownership Interests - Marengo Therapeutics
 
Jacques Moisan
Employment - Marengo Therapeutics
Leadership - Marengo Therapeutics
Stock and Other Ownership Interests - Marengo Therapeutics
 
Rajesh Chopra
Employment - Marengo Therapeutics
Leadership - Marengo Therapeutics
Stock and Other Ownership Interests - Marengo Therapeutics
 
Aurelien Marabelle
Stock and Other Ownership Interests - Centessa Pharmaceuticals; Deka Biosciences; HotSpot Therapeutics; Marengo Therapeutics; Shattuck Labs
Consulting or Advisory Role - Adagene; AstraZeneca; BiolineRx; Centessa Pharmaceuticals; Clover Biopharmaceuticals; Deka Biosciences; Depth Charge Therapeutics; EISAI; Grey Wolf Therapeutics; Gritstone Bio; Guidepoint Global; HiFiBiO Therapeutics; Hotspot Therapeutics; ImCheck therapeutics; Innate Pharma; Johnson & Johnson/Janssen; Lytix Biopharma; Medicxi; MSD; Neogene Therapeutics; OSE Immunotherapeutics; Pegaone; Pierre Fabre; Redx Pharma; Roche; Sanofi; SERVIER; Shattuck Labs; Sotio; Third Rock Ventures
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - Sotio
Other Relationship - Elsevier
 
Howard L. Kaufman
Employment - Ankyra Therapeutics
Leadership - Ankyra Therapeutics
Stock and Other Ownership Interests - Immuneering; Replimune
Honoraria - Society for Immunotherapy of Cancer
Consulting or Advisory Role - Castle Biosciences; Marengo Therapeutics; Midatech Pharma; Tatum Bioscience; Virogin Biotech
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Zhen Su
Employment - Marengo Therapeutics
Leadership - Marengo Therapeutics
Stock and Other Ownership Interests - Marengo Therapeutics
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Marengo Therapeutics (Inst); Merck (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje